Humberto Saavedra, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1503 Encino Ave, Alice, TX 78332 Phone: 361-396-0190 Fax: 361-396-0190 |
Suraj Govind Kamat, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1008 Medical Center Blvd, Alice, TX 78332 Phone: 361-668-4278 |
Usman Qureshi, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1008 Medical Center Blvd, Alice, TX 78332 Phone: 361-668-4278 |
Dr. David Cabell Gray, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2510 E Main St, Suite 104, Alice, TX 78332 Phone: 361-661-8390 Fax: 361-661-8395 |
News Archive
Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.
Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme classes, as well as chemical biology approaches for discovering small molecule inhibitors of these epigenetic enzymes, and demonstrate Epizyme's scientific leadership in the area of epigenetics.
The German Institute for Quality and Efficiency in Health Care already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previous treatment. In the new dossier compiled by the drug manufacturer, the drug was now compared with the appropriate comparator therapy dacarbazine specified by the Federal Joint Committee (G-BA) also for non-pretreated patients.
Frost & Sullivan released today its three big predictions for the global healthcare market. Based on a '2013 Search for Growth' survey which involved 1835 executives in more than 40 countries worldwide, Frost & Sullivan's insight highlights new areas of growth. mHealth, Cloud in Healthcare and Regulatory Environments will be the key subjects in 2014 and beyond.
Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International, today announced that it has now launched chlordiazepoxide hydrochloride and clidinium bromide, an authorized generic (AG) version of Librax®. Oceanside has received its first orders and expects to be a significant player in the Librax® generic market.
› Verified 2 days ago